Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nora Crikelair"'
Publikováno v:
Vascular Health and Risk Management, Vol 2010, Iss default, Pp 821-827 (2010)
Maurizio Destro1, Nora Crikelair2, Joseph Yen2, Robert Glazer 1Azienda Ospedaliera della Provincia di Pavia, Stradella (PV), Italy; 2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USAObjective: This post hoc analysis evaluated the ef
Externí odkaz:
https://doaj.org/article/84084ce0886541d586c9369ca6e85d9c
Autor:
Ian D, Pavord, Yamo, Deniz, Jonathan, Corren, Thomas B, Casale, J Mark, FitzGerald, Kenji, Izuhara, Nadia, Daizadeh, Benjamin, Ortiz, Robert R, Johnson, Sivan, Harel, Michel, Djandji, Ledia, Goga, Nora, Crikelair, Paul J, Rowe, William W, Busse
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 11:1213-1220.e2
Fractional exhaled nitric oxide (FeNO) may have a role both as a prognostic and predictive biomarker, in combination with eosinophils, for assessing responsiveness to some biological therapies.We evaluated the value of baseline FeNO, adjusted for bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ac8264734c7623e343b8ee0898e1f8
https://doi.org/10.1016/j.jaip.2022.11.043
https://doi.org/10.1016/j.jaip.2022.11.043
Autor:
Anju Peters, Hironori Sagara, Jonathan Corren, Christian Domingo, Nadia Daizadeh, Benjamin Ortiz, Michel Djandji, Paul Rowe, Juby Jacob-Nara, Nora Crikelair, Yamo Deniz
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:AB63
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e27d112d4bbad0455bd562f0256a2d9
https://doi.org/10.1016/j.jaci.2021.12.237
https://doi.org/10.1016/j.jaci.2021.12.237
Publikováno v:
Clinical Drug Investigation. 29:791-802
Baseline blood pressure (BP) is a strong predictor of response to antihypertensive therapy and the patient's ability to reach BP goals. The objective of this study was to evaluate the role of baseline BP as a determinant of systolic BP (SBP) and trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae3444585e4339cd1e24fcf1f88678e0
https://doi.org/10.2165/11530600-000000000-00000
https://doi.org/10.2165/11530600-000000000-00000
Publikováno v:
Advances in Therapy. 26:1012-1023
An 8-week trial of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) for moderate or severe hypertension demonstrated more-pronounced blood pressure (BP)-lowering effects compared with dual-component therapies. To elucidate the effects of time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8531a5e0921bc08d65a22d0794fb9c4
https://doi.org/10.1007/s12325-009-0077-7
https://doi.org/10.1007/s12325-009-0077-7
Publikováno v:
Journal of the American Society of Hypertension. 2:476-483
We evaluated the relationship between age and treatment response from pooled data from two randomized trials in which 1,464 patients with Stage 2 hypertension were treated with valsartan alone or in combination with hydrochlorothiazide (HCTZ). Multiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb2242613b6819a3478a2b4d81610b4
https://doi.org/10.1016/j.jash.2008.06.003
https://doi.org/10.1016/j.jash.2008.06.003
Publikováno v:
J Clin Hypertens (Greenwich)
Subgroup analyses were performed for the diabetic and nondiabetic cohorts from 3 randomized clinical trials that had evaluated the systolic blood pressure (SBP)-lowering efficacy and tolerability of an angiotensin receptor blocker, valsartan, alone o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b969fa6e62d0650aebb305755d42d0
https://doi.org/10.1111/j.1751-7176.2008.00003.x
https://doi.org/10.1111/j.1751-7176.2008.00003.x
Autor:
Venkatram Kuturu, Ricardo Rocha, Matthew R. Weir, Nora Crikelair, Drew Griffin Levy, Robert Glazer
Publikováno v:
J Clin Hypertens (Greenwich)
This patient data meta‐analysis included 9 randomized, double‐blind, placebo‐controlled trials (N=4278) of once‐daily valsartan 80, 160, or 320 mg or valsartan/hydrochlorothiazide 80/12.5, 160/12.5, 160/25, 320/12.5, or 320/25 mg given for 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f73aebf27faf45a783299ff9655265d
https://doi.org/10.1111/j.1524-6175.2007.06415.x
https://doi.org/10.1111/j.1524-6175.2007.06415.x
Publikováno v:
Journal of hypertension. 33(2)
Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f837f876c1fdf9d84eb822f6b1b0e617
https://pubmed.ncbi.nlm.nih.gov/25629366
https://pubmed.ncbi.nlm.nih.gov/25629366
Publikováno v:
Current medical research and opinion. 29(8)
To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fff6994b5e9e7688b0dffce8f8014fe
https://pubmed.ncbi.nlm.nih.gov/23721363
https://pubmed.ncbi.nlm.nih.gov/23721363